Investigation of radiation attenuation parameters of some drugs used in Chemotherapy in Wide Energy Region
Journal Title: Journal of Radiology and Oncology - Year 2018, Vol 2, Issue 2
Abstract
Objectives: The aim of this study is to compute the radiation attenuation parameters such as mass attenuation coefficient, linear attenuation coefficient, half value layer, mean free path, and effective atomic number for some selected chemotherapy drugs such as Lomustine, Cisplatin, Carmustine, and Chlorambucil in the energy range from 1 keV to 100 GeV.
Authors and Affiliations
F Akman, R Mustafa Kaçal
Keywords
Related Articles
- EP ID EP536263
- DOI 10.29328/journal.jro.1001021
- Views 112
- Downloads 0
Adaptive planning and toxicities of uniform scanning proton therapy for lung cancer patients
Purpose: Adaptive planning is often needed in lung cancer proton therapy to account for geometrical variations, such as tumor shrinkage and other anatomical changes. The purpose of this study is to present our findings i...
Which is the best? Palliative Radiation Therapy to Spleen or Splenectomy
Spleen is one of the most important organ of the reticuloendothelial system and coordinates the immune response. Splenectomy is performed for hypersplenism, and staging of hematological malignancy. In conservatively foll...
Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Ra-223 dichloride is a first-in-class alpha-emitting radiopharmaceutical recently introduced into clinical practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases. D...
Investigation of radiation attenuation parameters of some drugs used in Chemotherapy in Wide Energy Region
Objectives: The aim of this study is to compute the radiation attenuation parameters such as mass attenuation coefficient, linear attenuation coefficient, half value layer, mean free path, and effective atomic number for...
Near Complete Response to 177Lu-PSMA-DKFZ-617 Therapy in a Patient with Metastatic Castration Resistant Prostate Cancer
Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for the radionuclide therapy in advanced prostate cancer patients due to its high expression in the prostate cancer cells. We pre...